Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Beta-Hydroxyleucine is an optically active nonprotein alpha-amino acid and an analog of leucine. It functions as a research tool to investigate protein synthesis, processing, and enzyme activity. It has been shown to inhibit serine proteases like bovine trypsin and proteinase K, with competitive inhibition observed for trypsin. As a leucine analog, it can modulate the amino acid-sensitive TOR signaling pathway in adipocytes, stimulating 4E-BP1 phosphorylation. Its incorporation into nascent peptide chains can interfere with various protein processing events, including signal peptide function, dibasic cleavage of prohormones, and oligosaccharide processing, leading to altered protein conformation and secretion. Additionally, it has been implicated in the regulation of alpha-acetohydroxy acid synthetase activity in bacteria.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Beta-Hydroxyleucine.